September 2023 in “Journal of the European Academy of Dermatology and Venereology” This letter discusses the potential of the "Gabrin sign" as an indicator for identifying high-risk COVID-19 patients with androgenic alopecia, yet no specific results are detailed in the text.
November 2020 in “Journal of The American Academy of Dermatology” This article comments on previous studies linking severe androgenetic alopecia to increased vulnerability to COVID-19 and highlights ongoing research into antiandrogen therapies as potential treatments.
3 citations
,
November 2020 in “Journal of The American Academy of Dermatology” This paper discusses the proposal that androgenetic alopecia, as seen in the "Gabrin sign", could indicate higher risk of severe COVID-19 symptoms, but its validity is questioned and further confirmation is needed.
32 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study noted that among hospitalized COVID-19 patients, androgenetic alopecia was prevalent, and severe cases were associated with adverse outcomes such as respiratory failure, highlighting a possible link with androgen sensitivity.
119 citations
,
May 2020 in “Journal of The American Academy of Dermatology” This study observed a high prevalence of androgenetic alopecia in patients hospitalized with severe COVID-19, with 79% of men and 42% of women affected, suggesting a potential link between androgen sensitivity and COVID-19 severity.